Summary & Overview
HCPCS J9177: Enfortumab Vedotin-ejfv Injection, 0.25 mg
HCPCS Level II code J9177 denotes the injectable oncology drug enfortumab vedotin-ejfv, billed per 0.25 mg unit. This code is used to capture administration and acquisition costs for a targeted anticancer therapy delivered in outpatient infusion centers and oncology clinics. Nationally, biologic and specialty drug billing codes like J9177 matter because they drive specialty drug reporting, payer coverage determinations, and hospital and clinic reimbursement for high-cost oncology agents.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how J9177 is positioned within billing workflows, typical sites of service, and what to expect in payer coverage patterns. The publication provides benchmarks for unit-based drug billing, notes common modifier usage where applicable, and summarizes clinical context for enfortumab vedotin-ejfv as an intravenous/subcutaneous injectable oncology agent.
This national-level summary is intended to help billing managers, revenue cycle staff, and policy analysts understand code use, payer relevance, and areas to review in claims processing and coverage policies. Data not available in the input are noted where specific payer rates, taxonomies, ICD-10 pairings, and related codes would normally be detailed.
Billing Code Overview
HCPCS Level II code J9177 represents the medication enfortumab vedotin-ejfv administered by injection, billed per 0.25 mg unit. The service type is injectable oncology drug administration, typically provided in outpatient infusion centers or oncology clinic settings where specialty anticancer therapies are delivered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with locally advanced or metastatic urothelial carcinoma who has progressed after prior platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor, or another patient with advanced urothelial cancer meeting FDA-labeled indications for enfortumab vedotin-ejfv. The drug J9177 represents enfortumab vedotin-ejfv billed per 0.25 mg increment. Treatment is administered intravenously in an outpatient oncology infusion center, hospital outpatient department, or ambulatory infusion suite. The clinical workflow begins with oncology evaluation, verification of diagnosis and prior therapies, baseline laboratory testing (CBC, CMP), assessment of peripheral neuropathy and skin integrity, and consent. On treatment day the patient is prepped, line/access is confirmed, and the prescribed dose (calculated by weight or body surface area and converted to billable units of 0.25 mg) is prepared by pharmacy under sterile conditions. The infusion is delivered by an oncology nurse with monitoring for infusion reactions, dermatologic toxicity, hyperglycemia, and neuropathy. Post-infusion documentation includes lot number, units administered, site of service, applicable modifier(s), and any immediate adverse events. Follow-up visits include response assessment, toxicity management, and subsequent dosing every 3 weeks or as indicated by protocol or FDA labeling.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|